Postpartum Mh Htn denied as non-formulary by Humana?

Humana's specific coverage criteria for postpartum mh htn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Postpartum Mental Health and Hypertension Medications as Non-Formulary

Humana maintains a tiered drug formulary that is updated periodically. Medications for postpartum mental health conditions and postpartum hypertension may fall outside the formulary — or land on a higher cost-sharing tier — because a therapeutically similar drug is preferred. This is a business and cost-management decision, not a clinical judgment about whether your medication works. Non-formulary denials are among the most commonly reversed on appeal when a prescriber documents why the formulary alternative is not appropriate for you specifically.

## Why This Denial Is Appealable

Formulary exceptions exist for exactly this situation. Humana is required to have a formulary exception process and must grant one when the formulary alternative is clinically contraindicated, has been tried and failed, or is otherwise not appropriate for the enrollee's individual circumstances. Postpartum mental health and hypertension treatments are highly individualized — what is appropriate for one patient may carry meaningful risk for another (e.g., effects on breastfeeding). Your prescriber's individualized clinical rationale is the core of a formulary-exception appeal.

## Federal Appeal Framework

• Formulary exception request: File this first — it is faster than a formal appeal. Humana must respond within defined timeframes (typically 72 hours standard, 24 hours expedited).
• Internal appeal: If the exception is denied, you have the right to a full internal appeal under ERISA §503 or applicable state law.
• External review (ACA §2719): A final internal denial on a non-formulary exception is subject to independent external review within approximately four months. An IRO will evaluate whether the exception should have been granted.
• Expedited track: Request expedited review given the postpartum clinical context — symptom escalation risk supports urgency.

## Documentation to Gather

1. Formulary exception letter from prescriber: Explaining why the Humana-preferred formulary alternative is not clinically appropriate for you (e.g., inadequate efficacy in your case, documented intolerance, breastfeeding safety considerations per the FDA label). 2. Trial-and-failure records: If you previously tried the formulary alternative, provide dates, doses as recorded in your chart, and the documented outcome or adverse effect. 3. FDA prescribing label: Confirm the indication, and note any population-specific language relevant to postpartum patients that supports the choice of the non-formulary agent. 4. Diagnosis and severity documentation: Records confirming your postpartum mental health and/or hypertension diagnosis and current clinical status.

## Criteria-Mapping Structure

Obtain Humana's formulary exception criteria from the Evidence of Coverage or by calling member services. Map each criterion to your chart evidence:

| Humana Exception Criterion | Your Supporting Evidence | |---|---| | Formulary alternative is contraindicated or inappropriate | [Prescriber letter, FDA label reference, clinical note] | | Formulary alternative was tried and failed | [Medication name, dates, chart outcome note] | | Clinical urgency / postpartum context | [Diagnosis date, severity documentation] |

Attach the FDA-approved prescribing label for the requested medication, flagging the relevant indication language, and Humana's own published coverage policy alongside your completed criteria map.